

1 **Metabolomics reveals reasons for the efficacy of acupuncture in**
2 **migraine patients: The role of anaerobic glycolysis and mitochondrial**
3 **citrate in migraine relief**

4 Zishan Gao^{1,2,3,4*}, Xianzhong Yan⁵, Rui Wang-Sattler^{1,2}, Marcela Covic^{1,2}, Guang Yu⁶,
5 Feifei Ge⁷, Jia Lin⁸, Qin Chen⁹, Juan Liu⁵, Sapna Sharma^{1,2}, Sophie Molnos^{1,2}, Brigitte
6 Kuehnel^{1,2}, Rory Wilson^{1,2}, Jonathan Adam^{1,2}, Stefan Brandmaier^{1,2}, Shuguang Yu¹⁰,
7 Ulrich Mansmann⁴, Fanrong Liang^{11*}, Christian Gieger^{1,2*}

8 1 Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German
9 Research Center for Environmental Health, Neuherberg, Bavaria, Germany

10 2 Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for
11 Environmental Health, Neuherberg, Bavaria, Germany

12 3 Department of Clinical Acupuncture and Moxibustion, Nanjing University of Chinese
13 Medicine, Nanjing, Jiangsu 210029, China

14 4 Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-
15 Maximilians University Munich, Munich, Germany

16 5 National Center of Biomedical Analysis, Beijing 100039, China

17 6 Department of Biochemistry and Molecular Biology, School of Medicine & Holistic
18 Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029,
19 China

20 7 Department of Human Anatomy and Histoembryology, School of Medicine & Holistic
21 Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029,
22 China

23 8 Department of Biochemistry and Molecular Biology, West China School of Basic
24 Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, Sichuan 610041,
25 China

26 9 The Third Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou,
27 Zhejiang 310006, China

28 10 Acupuncture & Chronobiology Key Laboratory of Sichuan Province, Chengdu
29 University of Traditional Chinese Medicine, Chengdu, Sichuan 610075, China

30 11 Acupuncture and Tuina School/The 3rd Teaching Hospital, Chengdu University of
31 Traditional Chinese Medicine, Chengdu, Sichuan 610075, China

32

33 **For correspondence:** zishang30@sina.cn;christian.gieger@helmholtz-muenchen.de;
34 acuresearch@126.com

35

36 **Competing interest:** The remaining authors declare competing no financial interests.

37

38 **Abstract**

39 Acupuncture is used worldwide to treat migraine, but its scientific mechanism remains
40 unclear. Here, we report a 1H NMR metabolomics study involving 40 migraine patients
41 and 10 healthy people randomly receiving acupuncture or sham acupuncture, followed by
42 machine learning techniques and functional analysis. We found that acupuncture at
43 acupoints particularly enhanced anaerobic glycolysis and modified mitochondrial
44 function by adjusting the levels of plasma pyruvic acid ($P = 0.012$), lactic acid ($P =$
45 0.031) and citrate ($P = 0.00079$) at a Bonferroni-corrected level of significance compared
46 to the pre-treatment level of these three metabolites in migraine patients. Therefore,
47 acupuncture supplies energy to migraine patients and relieves migraine attacks. In
48 contrast, we observed that sham acupuncture may partially supply energy to migraine
49 patients through lipid metabolism by changing the levels of plasma lipid ($P = 0.0012$),
50 glycerine ($P = 0.021$), and pyruvic acid ($P = 0.047$) at a Bonferroni-corrected level of

51 significance. The functional network analysis further indicates this different way of
52 supplying energy contributes to the different effects of acupuncture and sham
53 acupuncture. Our findings reveal novel metabolic evidence for the specific effect of
54 acupuncture in relation to sham acupuncture. This metabolic evidence could enlighten a
55 brand new direction into acupuncture analgesia mechanism, which in turn would pose
56 fresh challenges for future acupuncture research.

57 **Keywords:** migraine; acupuncture; metabolomic; anaerobic glycolysis; citrate; lactic acid

58

59 **Introduction**

60 Acupuncture is commonly used for preventing and relieving migraine worldwide
61 (Wells *et al.*,2011). Understanding the mechanism underlying the efficacy of acupuncture
62 for migraine is key to the acceptance of acupuncture as valid therapy for both Western
63 doctors and policymakers. Recently, a rich source of clinical evidence has demonstrated
64 the effectiveness and safety of acupuncture for migraine, showing that acupuncture could
65 effectively reduce the intensity of migraine, frequency of migraine attacks, and number of
66 migraine days (Linde *et al.*, 2016; Vickers *et al.*, 2012). In contrast to the abundant
67 evidence from those clinical trials, the biological basis for the efficacy of acupuncture in
68 relieving migraines remains unclear.

69 To date, several experimental studies have shown that acupuncture alleviates
70 migraine by activating a range of biochemicals in peripheral and pain-related central
71 nuclei (Goldman *et al.*, 2010; Zhao *et al.*,2017) . Goldman et al (2010) found that
72 adenosine and adenosine metabolism mediated the analgesic effect of acupuncture in a
73 mouse model. Zhao et al (2017) showed that calcitonin gene-related peptide (CGRP),
74 which plays a key role in triggering migraine, was suppressed by electroacupuncture in a
75 rat model of migraine. However, there is no validated biomarker associated with the

76 effects of acupuncture for migraine in clinical studies. The explicit biochemical pathways
77 or mechanisms addressing the process of acupuncture relief of migraine are not clear at
78 present. Further, the specific effect of acupuncture relative to sham acupuncture is a long-
79 standing controversial topic. Zhao L et al showed in a multicentre randomized trial that
80 acupuncture for migraine is more effective than sham acupuncture (Zhao *et al.*, 2017);
81 others, however, have found no differences (Linde *et al.*, 2005; Li *et al.*, 2012). An
82 individual patient data (IPD) meta-analysis including 20,827 patients confirmed that
83 acupuncture is statistically superior to sham acupuncture for migraine, but the difference
84 in effect size between acupuncture and sham was relatively small (Vickers *et al.*, 2012;
85 Vickers *et al.*, 2014). Due to the absence of explainable biological mechanisms for the
86 specific effects of acupuncture, the acceptance of acupuncture as a referable therapy in
87 migraine management is still arguable (Linde *et al.*, 2017). Hence, two important
88 questions are raised in this paper: first, are there any biomarkers or pathways that provide
89 a possible mechanism for the efficacy of acupuncture relieving migraine? Second, is
90 there any biological basis attributed to the specific effect of acupuncture compared with
91 sham acupuncture for relieving migraine?

92 Recently, a large number of studies resumed investigation of the pathogenesis of
93 migraine, emphasizing that abnormalities in energy metabolism and mitochondrial
94 function are the fundamental milestones in the pathophysiology of migraine (Colombo *et*
95 *al.*, 2014; Lodi *et al.*, 2006; Sparaco *et al.*, 2006). Increasing experiments have revealed
96 that insufficient cerebral glycogen unbalances energy metabolism, leading to inhibition of
97 astroglial mitochondrial respiration and excessive production of free radicals. These
98 metabolic changes are attributed to further energy failure in neurons that stimulate
99 cortical expansion depression (CSD) and thus trigger migraine (Finsterer *et al.*, 2018).
100 Moreover, previous studies indicated that the effect of acupuncture may involve multiple

101 pathways and dynamic system changes from genomics to metabolomics (Xu *et al.*, 2012).
102 Metabolomics has been powerfully utilized to reveal potential metabolic biomarkers of
103 acupuncture for hypertension (Yang *et al.*, 2018), functional dyspepsia (Wu *et al.*, 2016)
104 and chronic atrophic gastritis (Luo *et al.*, 2013). As such, it is therefore essential to
105 employ metabolomic approaches to pinpoint crucial biomarkers and elucidate the
106 systemic mechanism of acupuncture effects for migraine. Our previous study
107 demonstrated that acupuncture could adjust metabolic profiling in an acute migraine rat
108 model (Gao *et al.*, 2014). Nevertheless, the challenge from statistical methods for dealing
109 with high-dimensional metabolomic data still limits the use of metabolomics in
110 acupuncture research. Within this context, machine learning techniques, such as the least
111 absolute shrinkage and selection operator (Lasso), are promising tools for reducing high-
112 dimensional data and selecting accurate biomarkers for metabolomics (LeWitt *et al.*,
113 2017; Menni *et al.*, 2017).

114 To investigate the potential metabolic mechanism for the efficacy of acupuncture
115 relief of migraine, we employed ¹H- Nuclear magnetic resonance (NMR) metabolomic
116 technology to detect plasma metabolic phenotypes for 40 female migraine patients who
117 randomly received either acupuncture or sham acupuncture from a total of 476 patients in
118 a randomized controlled trial, together with a group of 10 healthy persons. Using
119 orthogonal signal correction for partial least square discriminate analysis (OPLS-DA), we
120 determined different metabolic profiles among healthy controls and migraine patients
121 treated with acupuncture or sham acupuncture. Next, we conducted Lasso regression to
122 select metabolic biomarkers for discriminating acupuncture and sham acupuncture and
123 validated the selected metabolites using analysis of variance (ANOVA) combined with
124 Box-Cox transformations and Bonferroni corrections. Further, we validated the
125 performance of Bonferroni-corrected significant metabolic biomarkers discriminating

126 migraine patients at baseline, healthy people and migraine patients after acupuncture in a
127 clinical setting by receiver operating characteristic (ROC) curve analysis. Finally, we
128 complemented our analysis with 2 Bonferroni-corrected significant metabolites and 2
129 discriminated metabolic pathways attributed to the specific effect of acupuncture using
130 Ingenuity Pathway Analysis (IPA), revealing a novel metabolic mechanism for the
131 efficacy of acupuncture in relieving migraine (Figure 1).

132

133 **Results**

134 **Baseline characteristics and clinical effects of acupuncture**

135 A total of 476 migraine patients were included in the multicenter trial (Li *et al.*,
136 2012), and 40 eligible female patients were enrolled in the 4-week baseline period and
137 randomized into the true electroacupuncture (EA) and sham electroacupuncture groups
138 (Sham EA) (22 in the EA group, 18 in the Sham EA group) of the metabolomic study.
139 These 40 patients finished the 4-week baseline assessment and the 4-week EA or Sham
140 EA treatment (Figure 1). There are 39 patients with migraine who meet the definition of
141 migraine without aura, only one migraine patient with aura was recruited in the study.
142 And this patient dropped out in the end of electroacupuncture treatment and not included
143 in the statistical analysis. The baseline characteristics and clinical outcomes were based
144 on the intention-to-treat (ITT) population in this study. We omitted the cases that retained
145 only the baseline measurement but had missing data in all clinical outcomes. No
146 significant difference between the two groups was found for any demographic
147 characteristics of all included patients, including age, sex, height, weight, or disease
148 status of the patients, such as duration of disease, number of days with migraine, and
149 visual analogue scale (VAS) that assesses pain severity (Table 1, Table S1).

150 After 4 weeks of EA treatment, patients in the EA group showed a significant
151 reduction in days ($P = 0.006$) and frequency ($P = 0.039$) of migraines as well as a

152 decrease in VAS scores for pain intensity ($P = 0.047$) compared to the baseline period
153 (Table 1). In contrast, patients in the Sham EA group also showed a decrease in all three
154 symptoms, but this decrease was not statistically significant ($P > 0.05$) (Table 1).
155 However, there was no significant difference between the EA group and the Sham EA
156 group in alleviating migraine (Table 1). Our results were consistent with the multicentre
157 trial of acupuncture for migraine by Yin Li (Li *et al.*, 2012). Since a significant difference
158 may not explain the real magnitude of the clinical effect of acupuncture, we further
159 calculated the effect size to validate the efficacy of acupuncture in the context of the
160 clinical setting (Zhao *et al.*, 2017).

161 After 4 weeks of treatment, the effect size measured by Cohen's D in the EA group
162 compared to the baseline period was 0.50 (95% CI, 0.17 to 0.82) for the reduction in the
163 number of migraine days, 0.71 (95% CI, 7.03e-05 to 1.41) for the decrease in the
164 frequency of migraines and 0.61 (95% CI, -0.26 to 1.47) for the decrease in VAS scores
165 (Table 1). In the context of our study, these effect sizes beyond 0.5 in the EA group
166 manifested that the effect sizes in the EA group are, on average, 0.5 standard deviations
167 greater for relieving those symptoms of migraine than those during the baseline period
168 (Ben *et al.*, 2020). However, the effect sizes in the Sham EA group compared to the
169 baseline period were 0.65 (95% CI, -0.042 to 1.34) for the reduction in the number of
170 migraine days, 0.36 (95% CI, -0.44 to 1.17) for the decrease in frequency of migraines
171 and 0.14 (95% CI, -0.36 to 0.63) for the decrease in VAS scores (Table 1). These results
172 of effect size were partly in accordance with the large IPD meta-analysis by Vickers *et al*
173 (Vickers *et al.*, 2012), although they were not statistically significant. Specifically, the
174 effect size in the EA group was 0.585 (95% CI, -0.19 to 1.36) compared to the Sham EA
175 group, which means that the EA group is, on average, 0.585 standard deviations greater
176 for decreasing VAS scores than the Sham EA group (Table 1).

177

178 **Metabolic discrimination between migraine and healthy controls**

179 We employed ^1H NMR techniques and Chenomx NMR Suite 4.5 (Chenomx,
180 Calgary, Canada) to identify 22 metabolites that were measured in a total of 50 plasma
181 samples from migraine patients in the baseline period (MA, $n = 40$) and healthy controls
182 ($n = 10$) (Figure 2 and Table 2). After excluding outliers of abnormal metabolic profiles
183 and baseline values among included migraine patients using PCA analysis, we first
184 performed orthogonal signal correction for partial least square discriminate analysis
185 (OPLS-DA) on the normalized Carr-Purcell-Meiboom-Gill (CPMG) NMR data to
186 distinguish metabolic profiles of migraine patients in the baseline period from the profiles
187 of the healthy controls. By using SIMICA-P statistical software, OPLS-DA analysis
188 demonstrated a distinct separation between the MA group and healthy controls (Figure
189 3A x-axis; $R^2Y = 75.8\%$). For the above score plot, R^2Y manifested the proportion of the
190 variance in the y variable explained by the regression model (Wang *et al.*, 2014). Thus,
191 the separation in the plot manifested a crucial metabolic phenotype difference between
192 migraine patients and healthy controls. Correspondingly, the loading plot showed the
193 information of the possible metabolites separating the metabolic profiling (Figure 3B),
194 such as glycine, glutamine, and alanine. After we identified the distinct metabolites in the
195 loading plot, we subsequently conducted Lasso regression, ANOVA combined with Box-
196 Cox transformations and Bonferroni correction on the CPMG dataset to further explore
197 potential metabolic biomarkers separating the profiles of migraine patients and healthy
198 controls. The dominant metabolites that discriminate these two groups are presented in
199 Table 2. After Bonferroni correction, we found a significant increase in 5 plasma
200 metabolites, including glycerine ($P = 0.00085$), choline ($P = 0.004$), citrate ($P = 0.016$),
201 pyruvic acid ($P = 0.049$) and glutamine ($P = 0.0017$), and a significant decrease in 3

202 plasma metabolites, including glycine ($P = 0.0017$), alanine ($P = 0.002$), and lipid ($P =$
203 0.030) in the MA group compared to healthy controls. We further conducted ROC curve
204 analysis to validate the clinical importance of these biomarkers. The result of the ROC
205 curve analysis showed that citrate performs well in differentiating between migraine
206 patients and healthy persons (area under the curve (AUC) = 0.87, $P = 0.005$) (Figure 4C).

207 Moreover, we conducted OPLS-DA analysis on the ^1H NMR longitudinal eddy
208 current delay (LED) dataset, and the LED results also illustrated a similar separation
209 between the MA group and the healthy control group (Supplementary Figure 2C and
210 Supplementary Table 2; $R^2Y = 99.7\%$). Accordingly, we found a significant decrease in
211 plasma N-acetyl glycoproteins (NAc) ($P=0.00082$) and a significant increase in plasma
212 phosphatidylcholine (Ptdcho) ($P = 0.035$) in the MA group compared to the healthy
213 control group after Bonferroni correction (Table S2). These significantly changed
214 metabolites found in the CPMG and LED results were selected as potential biomarkers
215 for the metabolic features of migraine in the clinical setting.

216

217 **Acupuncture reversing metabolic profiling and plasma citrate of migraine**

218 The main objective of our study was to investigate the possible metabolic
219 mechanism for the effectiveness of acupuncture treatment for migraine. Thus, after
220 demonstrating the metabolic profiling of migraine patients, we next explored whether
221 acupuncture changed the metabolites of migraine patients after 20 sessions of EA
222 treatment. Similarly, we performed OPLS-DA analysis on metabolomic data between
223 migraine patients during the baseline period (MA; $n = 22$) and migraine patients after
224 acupuncture treatment (EA; $n = 22$). To determine the trend of acupuncture altering
225 metabolites, we also conducted an OPLS-DA analysis on the metabolomic data of the
226 two aforementioned groups and 10 healthy controls ($n = 10$). After 20 sessions of EA at

227 Shaoyang Meridian acupoints over 4 weeks, we observed that the metabolic profiles of
228 the EA group were close to those of the healthy control group but differed from those of
229 the group at baseline (Figure 3C; $R^2Y = 94.5\%$), showing that EA restores the metabolic
230 profiles of migraine similar to those of healthy controls. We further achieved a clear
231 discrimination in metabolic profiling between migraine patients during the baseline
232 period and migraine patients after acupuncture treatment (Figure 3D; $R^2Y = 85.2\%$).
233 Notably, we demonstrated a significant decrease in the plasma levels of citrate ($P =$
234 0.00079) and pyruvic acid ($P = 0.012$) in the EA group compared to the MA group after
235 Bonferroni correction (Table 3). This result indicated that EA relieves migraine by
236 altering the levels of plasma citrate and pyruvic acid in the clinical setting. In addition,
237 we found a significant increase in plasma lactic acid ($P = 0.031$) and a significant
238 decrease in plasma acetoacetate ($P = 0.025$) in the EA group relative to the group at
239 baseline before EA treatment. Further, we found that glycerine ($P = 0.00016$) was
240 significantly elevated in the EA group compared to the healthy control (Table 3). These
241 significantly changed metabolites were potential metabolite biomarkers for EA relieving
242 migraine. The LED data also showed a clear differentiation between migraine patients
243 during the baseline period and migraine patients after acupuncture treatment (Figure S2C;
244 $R^2Y = 99\%$). A significant decrease in NAC ($P = 0.00073$) was found in the EA group
245 compared with the healthy control group after Bonferroni correction (Table S3). Taken
246 together, these data demonstrated that EA could enhance anaerobic glycolysis by
247 lowering the plasma levels of citrate and pyruvic acid as well as increasing the plasma
248 level of lactic acid. These regulations in energy metabolism and the tricarboxylic acid
249 cycle (TCA) cycle may be the basis of how acupuncture restores metabolic profiles and
250 relieves migraine in a clinical setting.

251

252 **Metabolic basis for the specific effect of acupuncture**

253 The second objective of our study was to detect the metabolic basis for the specific
254 effect of acupuncture in comparison with sham acupuncture. To address this question, we
255 next performed an OPLS-DA analysis on both CPMG and LED data comparing true
256 acupuncture (EA, n = 22) and sham acupuncture (Sham EA, n = 18) groups. To
257 distinguish the trend of acupuncture adjusting metabolic profiles, OPLS-DA analysis was
258 performed on metabolomic data from healthy controls (n = 10), true acupuncture (EA, n
259 = 22), and sham acupuncture (Sham EA, n = 18) groups. After 20 sessions of Sham EA
260 treatment on non-acupoints for 4 weeks, we found that the metabolic profile of the Sham
261 EA group (patients in the Sham EA group after treatment; n = 18) was separated from the
262 healthy controls but similar to the MA group (patients in the Sham EA group before
263 treatment; n = 18) (Figure 3E, $R^2Y = 48.9\%$). Moreover, the OPLS-DA analysis was
264 unable to differentiate MA group and Sham EA group (Figure 3F, $R^2X = 89.9\%$). In
265 addition, the OPLS-DA results also demonstrated an important discrimination in
266 metabolic profiling among EA, Sham EA and healthy controls (Figure 3G; $R^2Y = 88.5\%$),
267 which illustrated that the metabolic profiling of the EA group was close to the healthy
268 controls in relation to the Sham EA group. The difference in the metabolic profiles
269 suggested that EA treatment, not Sham EA treatment, could reverse the metabolic
270 profiles of migraine patients to healthy controls. Further, the OPLS-DA results showed a
271 clear separation of the metabolic profiles between the EA group and Sham EA group
272 (Figure 3H, $R^2Y = 94.8\%$), which indicates a discriminated metabolic phenotype between
273 acupuncture and sham acupuncture. The cross-validation for the OPLS-DA analysis of
274 the aforementioned groups was conducted using CV-ANOVA within SIMICA-P
275 software, and the results are provided in Supplementary Table S6.

276 Corresponding to the OPLS-DA analysis, after Bonferroni correction, ANOVA
277 results showed a significant decrease in pyruvic acid ($P = 0.047$) in the Sham EA group
278 compared to the MA group (Table 4). Similarly, we found a significant decrease in lipid
279 ($P = 0.0012$), glycine ($P = 0.000013$), and alanine ($P = 0.0016$) as well as a significant
280 increase in glycerine ($P = 0.021$) and glutamine ($P = 0.000013$) in the Sham EA group
281 compared with the healthy control (Table 4). These metabolite changes induced by Sham
282 EA reflect the potential metabolic basis for the effect of sham acupuncture on migraine.
283 Specifically, by using Lasso regression analysis, glycine, glycerine, alanine, 3-
284 hydroxybutyric acid (3-HB), isoleucine (leu_ile), low density lipoprotein_very low
285 density lipoprotein (LDL_VLDL), acetoacetate and glutamine were further selected as
286 potential biomarkers for the discrimination of EA and Sham EA (Table 5). Notably, we
287 found that glutamine ($P = 0.0098$) was significantly decreased in the EA group compared
288 to the Sham EA group (Table 5). Combined, these data demonstrate that there is a distinct
289 metabolic difference between EA and Sham EA. These metabolic differences, which can
290 be caused by plasma changes in glycine, glycerine, alanine, 3-HB, leu_ile, LDL_VLDL,
291 acetoacetate, and glutamine, are a potential metabolic basis for the specific effects of
292 acupuncture.

293

294 **Functional regulation and network adjustment by acupuncture**

295 After pinpointing the potential metabolic biomarkers for the clinical efficacy of
296 acupuncture, we conducted a metabolic pathway and network analysis among the healthy
297 control, MA, EA and Sham EA groups to further explore the potential upstream
298 pathological mechanisms of acupuncture for migraine. By using IPA, we observed a
299 significant change in the tRNA charging pathway ($P = 0.031$) and a top-changed
300 metabolic network of carbohydrate metabolism, molecular transport, and small molecule

301 biochemistry (score = 14) (Krämer *et al.*, 2014) between the healthy control and MA
302 groups (Figure S3A, D).

303 After 20 sessions of EA treatment for 4 weeks, we found that the pyruvate
304 fermentation to lactate pathway ($P = 0.0175$) was significantly reversed between the MA
305 and EA groups and that the carbohydrate metabolism, energy production, and lipid
306 metabolism networks (score = 9) were the top changed networks between the MA and
307 EA groups (Figure S3B, E). These results manifested that acupuncture reversed the levels
308 of citrate and pyruvic acid through pyruvate fermentation to the lactate pathway, and
309 changed the similar carbohydrate metabolism network, which was altered in migraine
310 patients compared to healthy controls. The changed network of energy production in the
311 EA group further supports the effect of EA based on regulations in energy metabolism
312 from our previous results. Specifically, we found that the tRNA charging pathway ($P =$
313 0.0307) was significantly discriminated between the EA group and Sham EA group
314 (Figure S3C), and the top network discriminating the EA group and Sham EA group was
315 carbohydrate metabolism, molecular transport, and small molecule biochemistry (score
316 =14, Figure 4C). Glycerine was located near the center of the metabolic network of EA
317 compared to Sham EA (Figure 4C). These findings indicate that the metabolic difference
318 found between EA and Sham EA treatment was linked to the tRNA charging pathway
319 and carbohydrate metabolism, molecular transport, and small molecule biochemistry.
320 These significantly changed metabolic pathways and networks may be the functional
321 basis of the specific effects of EA compared with sham EA.

322 **Discussion**

324 Here, we have described the first metabolomic study of acupuncture for migraine
325 derived from a randomized controlled trial. By using validated NMR techniques and
326 well-designed machine learning strategies, we demonstrated that EA at acupoints could

327 restore energy deficiency and adjust plasma citrate levels, thereby alleviating migraine.
328 Using advanced Lasso regression models, we first determined 8 metabolic biomarkers
329 that can be attributed to the potential metabolic basis for specific effects of acupuncture
330 compared to sham acupuncture. Taken together, these results demonstrated a distinct
331 metabolic phenotype that can serve as a novel scientific explanation for the efficacy of
332 acupuncture in the clinical setting.

333 The strength of this study includes a concealed central randomization and strict
334 machine learning statistical strategy. Compared with other metabolomics studies for
335 acupuncture, the use of central randomization in our study could minimize the selection
336 bias, and the independent of statistician could also lower the detection bias, thus improve
337 the reliability and validity of our study result in clinical setting (Zhao *et al.*,2017).
338 Specially, Lasso regression was executed, to eliminate the multicollinearity between
339 metabolites and the inter-metabolite relationships comprising the metabolic network
340 (LeWitt *et al.*,2017, Menni *et al.*, 2017). By using this shrinkage method, 8 potential
341 biomarkers distinguishing the acupuncture and sham acupuncture can be selected.
342 Moreover, Box-cox transformation was applied before the ANOVA analysis, which
343 could be a powerful procedure for adjusting skewed distributions and continuous
344 variables, thereby improving accuracy of statistical results (Yu *et al.*,2022). Further,
345 Bonferroni correction, one of the strictest multiple testing correction methods, was
346 executed in the study. This method not only could control the false positive rate, but also
347 pinpointed the validated biomarker for acupuncture (Sedgwick *et al.*,2014). Simply put,
348 we presented a novel and practical machine learning strategy in a randomized
349 acupuncture trial, which could set a possible example for handling high-dimensional
350 metabolomics data in acupuncture trials.

351 In this study, we found that EA was more clinically important to patients than sham
352 EA, especially for relieving the intensity of pain in migraine patients. First, EA, not sham
353 EA, could significantly alleviate these clinical symptoms in migraine. Second, the effect
354 size of the VAS score for pain relief in the EA group was markedly higher than that in the
355 Sham EA group (Table 1). The EA group showed an average decrease of 1.05 cm more
356 in the total 10 cm VAS compared with the Sham EA group, and this decrease reached the
357 1 cm MID in the VAS scale (Thorlund K *et al.*, 2011), which accounted for 10.5%
358 greater pain relief than Sham EA treatment at clinic. These results were further in
359 agreement with a long-term randomized trial on acupuncture for migraines (Zhao *et*
360 *al.*,2017). In addition, the nonsignificant results observed in both acupuncture groups
361 after treatment can be attributed to the limit of statistical significance for small sample
362 sizes as well as the penetration needles in sham EA, which had already been analyzed in
363 a large IPD meta-analysis (Vickers *et al.*, 2012; Li *et al.*, 2012).

364 Recently, accumulating evidence has confirmed that energy deficiency and
365 mitochondrial dysfunction are two cornerstones of migraine pathophysiology (Lodi *et*
366 *al.*,2006; Sparaco *et al.*,2006). A novel metabolic picture of migraine has been presented
367 in a publication of Nature Reviews Neurology (Gross *et al.*,2019): Decreased cerebral
368 glycogen prolonged synaptic activity, increased cerebral excitability, reduced CSD
369 threshold, and thus stimulated CSD in migraine. On the other hand, mitochondrial
370 dysfunction induced excessive production of free radicals and subsequently activated
371 transient receptor potential (TRP) channels that increase CGRP release, which is pivotal
372 for mediating migraine attack. Compared with former studies, we have shown enhanced
373 aerobic glycolysis and reduced gluconeogenesis, which trigger the increase in citrate as a
374 key intermediate in the TCA cycle and lead to mitochondrial energy metabolism disorder
375 in migraine patients. Lipid metabolism is also affected and disordered, accompanied by

376 an increase in fat mobilization, glycerine and ketone bodies (Table 2, Figure 5) (Aurora *et*
377 *al.*,2007; Bélanger *et al.*, 2011). These findings further detailed the imbalance between
378 reduced energy supplies and increased energy needs among migraine patients (Figure 5).
379 In addition, we demonstrated that citrate performed well in discriminating migraine
380 patients and healthy controls, revealing a potential novel biomarker for migraine. It has
381 been shown that an increase in citrate could activate transient receptor potential channel
382 A1 (TRPV1) pain receptors, enhance the protein kinase B (AKT) signaling pathway
383 (Figure S3D) (Gross *et al.*, 2019; Liu *et al.*, 2017; Xu *et al.*, 2018; Chen *et al.*, 2017) ,
384 thereby trigger migraine (Table 2, Figure 5). Collectively, our findings not only expanded
385 the pathophysiology of migraines with an additional understanding of metabolism, but
386 also highlighted the demands of efficient metabolic strategies for migraine treatment.

387 Previously, there is little understanding about the metabolic basis of acupuncture in
388 relieving migraine. Here, we provided novel metabolic evidence of EA relieving
389 migraine as follows: (i) EA could enhance anaerobic glycolysis through converting
390 increased pyruvic acid into lactic acid and subsequently decrease the elevated level of
391 citrate in the TCA cycle and acetoacetate in lipid metabolism in migraine patients (Figure
392 5). (ii) Importantly, citrate, which was found to be significantly increased in migraine
393 patients, was significantly decreased after EA treatment, which provides direct metabolic
394 evidence of EA adjusting mitochondrial function in migraine (Table 2, Figure 5). To date,
395 both experimental and clinical evidence has shown that the depletion of glycogen and
396 hypoglycaemia can trigger migraine attacks (Lodi R *et al.*, 2006; Pearce *et al.*, 1971;
397 Hockaday *et al.*, 1971). And lactic acid is a prior energy source for neurons during brain
398 energy deficiency (Suzuki *et al.*, 2011). Therefore, the first possible metabolic
399 mechanism for EA relieving migraine is the increased anaerobic glycolysis caused by EA
400 combined with the increase in lactic acid, which can quickly compensate for the lack of

401 energy and thereby possibly reduce the CSD triggering migraines (Figure 5).
402 Accordingly, a PET-CT study (Zeng *et al.*,2012; Yang *et al.*,2012) also revealed that EA
403 could restore glucose metabolism in key regions of the descending pain modulation
404 system (DPMS) of brain for migraine. Interestingly, our findings identified a potential
405 subgroup of migraine patients with a distinct metabolic phenotype that could benefit from
406 EA treatment in clinics. Moreover, previous results have indicated an important role of
407 mitochondrial dysfunction in migraine and the positive association between citrate levels
408 and activation of the AKT signaling pathway (Gross *et al.*, 2019; Liu *et al.*, 2017; Xu *et*
409 *al.*, 2018; Chen *et al.*, 2017) . Recent animal experiment further demonstrated inhibition
410 of the activation of AKT could attenuate cumulative pain score and pain-related
411 behaviors (Xu *et al.*, 2019). Thus, the second potential metabolic evidence of EA
412 managing migraine is that EA could adjust mitochondrial dysfunction and inhibit the
413 pain-related AKT pathway by decreasing the plasma level of citrate, thereby alleviating
414 pain in migraine (Figure 5). In particular, this metabolic biomarker of citrate may serve as
415 the desired quantitative biomarker for further clinical acupuncture research. Third, in the
416 previous decades, profound acupuncture experiments focused on the pivotal role of
417 opioid peptides and its related Arc-PAG-NRM-spinal dorsal horn pathway in mediating
418 acupuncture analgesia (Zhao *et al.*,2008; Huang *et al.*,2002). Compared to those
419 neurological evidence of acupuncture analgesia, our results revealed a systemic
420 modulation effect of EA on both energy metabolism and mitochondrial function in
421 migraine patients. These findings opened exceptional new insights into the metabolic
422 mechanism underlying the effectiveness of acupuncture analgesia and could be developed
423 into potent non-opioid drugs and multi-metabolic therapeutic targets for future migraine
424 treatment.

425 The specific effect of acupuncture is another long-debated issue among clinical
426 acupuncture trials. Fei Y et al and Prof. Gordon Guyatt pointed out in the publications of
427 BMJ that one of the specific methodology challenges in acupuncture trials is the
428 estimation for the optimal treatment effect of acupuncture compare to sham acupuncture
429 (Fei *et al.*, 2022). Here, we presented a unique metabolic mechanism for the specific
430 effect of acupuncture: We demonstrated that there are important but different ways of
431 energy supply between EA and Sham EA for relieving migraine. (i) EA specifically
432 reversed the deficiency of energy metabolism in migraine patients through anaerobic
433 glycolysis compared with Sham EA. In detail, EA can restore energy deficiency by
434 enhancing anaerobic glycolysis and decomposition of acetoacetate (Table 2, Figure 5) in
435 the plasma (Salek *et al.*,2017; Peek *et al.*,2020), which could quickly compensate for the
436 lack of energy and thereby reduce the CSD triggering migraine. In contrast, sham EA
437 may partially supply energy to migraine patients by fat mobilization through lipid
438 metabolism (Table 3). In addition, the network analysis showed that glycerine, a classic
439 product of fat mobilization, was the key node in the metabolic network of EA compared
440 with sham EA (Figure 4C). Therefore, we can postulate the hypothesis that these
441 different ways of supplying energy may be one of the crucial factors contributing to the
442 different effect between acupuncture and sham acupuncture. (ii) EA specifically relieves
443 migraine by reversing citrate, thereby adjusting mitochondrial dysfunction compared with
444 sham EA. The TCA cycle is the centre of energy metabolism in the body. In particular,
445 we have shown that EA, not sham EA, could reverse plasma citrate and subsequently
446 adjust the dysfunction of the TCA cycle in mitochondria, thus restoring metabolic
447 profiling and relieving migraine in migraine patients (Figure 5). (iii) We found that
448 glutamine, a classic excitatory neurotransmitter that facilitates CSD and is linked to the
449 intensity of migraine (Gao *et al.*,2014; Aroke *et al.*,2020; Alam *et al.*,1998), showed a

450 Bonferroni-corrected significant decrease in the EA group compared with the Sham EA
451 group. This result is consistent with our previous metabolomic study of an acute migraine
452 rat model (Gao *et al.*,2014). The significant decrease in glutamine in the EA group
453 relative to the Sham EA group further explains why EA had a better clinical migraine
454 pain relief effect than sham EA. In addition, our study found that both EA and sham EA
455 could significantly increase glycerine levels, thereby supplying energy to migraine
456 patients. This finding gives a possible explanation for the non-specific effect of EA and
457 sham EA observed in these clinical trials. Collectively, the specific effect of EA on both
458 anaerobic glycolysis and mitochondrial function for migraine exclusively provides a
459 possible scientific mechanism of the efficacy of acupuncture for clinical doctors and
460 clinical decision-makings.

461 In summary, our findings indicate that EA specifically relieves migraine by
462 enhancing anaerobic glycolysis and decreasing the plasma levels of citrate and glutamine
463 among migraine patients. Our study is of great importance because it provides scientific
464 evidence and explanations for the specific effect of acupuncture relieving migraine for
465 both clinical doctors and policymakers. By applying modern machine learning
466 techniques, this metabolic evidence could enlighten a brand new direction into
467 acupuncture analgesia mechanism, which in turn would pose fresh challenges for future
468 acupuncture researches.

469

470 **Limitations of the study**

471 The main limitation of this study is the limited sample size and the non-targeted
472 metabolic technique which cannot detect targeted metabolite changes in the TCA cycle
473 and glucose metabolism. And the validated animal experiment should also be executed.

474 Future studies will extend this work using a larger sample size of migraine patients and
475 targeted metabolomics on both human and animals for possible validation experiments.

476

477 **Materials and methods**

478 **Ethics approval**

479 The clinical trial protocol was approved by the Ethics Review Committee of the 1st
480 Teaching Hospital of Chengdu University of TCM and had been published [2007KL-
481 002] (Li *et al.*, 2008). The multicentre randomized trial was registered (clinicaltrials.gov:
482 NCT00599586). All study procedures were designed and conducted in accordance with
483 principles of the Declaration of Helsinki and the Chinese version of the International
484 Conference on Harmonisation --- Good Clinical Practice. All patients signed written
485 informed consent.

486

487 **Participants**

488 From April 1, 2008, to August 12, 2009, 476 migraine patients were recruited in the
489 multicentre trial. And the migraine patients included in this metabolomic study were all
490 recruited from a single trial centre, the 1st Teaching Hospital of Chengdu University of
491 TCM, which is one of the clinical centers in the multicentre trial. To be included, the
492 migraine patients had to meet the International Headache Classification criteria for
493 migraines (ICHD-II 2004) (Headache Classification Subcommittee of the International
494 Headache Society, 2004), as diagnosed by a doctor. The inclusion criteria were as
495 follows: age from 20 to 45 years old; female only; Han nationality; onset of migraines
496 before age 45; more than 1 year of migraine history and acute migraine attacks 2 to 8
497 times per month during the previous three months; no use of any prophylactic drug for
498 migraine during the previous 2 weeks; body mass index (BMI) ranging from 18-24; no
499 heart, liver, or kidney disease detected by ultrasound or blood tests as well as other

500 serious organic diseases; willingness to complete 20 acupuncture treatments for 4 weeks;
501 and ability to provide written informed consent.

502 We excluded patients who had headache owing to organic disorders (e.g.,
503 cerebrovascular disease, vascular malformation, arthritic conditions, arteriosclerosis or
504 hypertension) or patients with psychosis, pregnancy or lactation, allergies, bleeding
505 disorders or serious diseases of the heart, liver, kidney or other organs.

506 Healthy females without migraine who had no significant differences in age, gender,
507 or BMI compared to migraine patients were recruited as the healthy control group.

508

509 **Randomization and interventions**

510 The overall trial approach is shown in Figure 1. Forty female patients who met the
511 inclusion criteria were randomly assigned to the electroacupuncture group at specific
512 acupoints belonging to the Shaoyang Meridian group (EA) or the electroacupuncture
513 group at non-acupoints (Sham EA) using a central randomization procedure controlled by
514 the Chengdu Good Clinical Practice (GCP) Center. Central randomization was conducted
515 by a GCP center computer. The independent study assistant sent the patient's information
516 to the GCP centre through email or short message service (SMS) message. Random
517 numbers and group assignments were accordingly generated by a GCP computer and sent
518 back to the study assistant by a feedback email or SMS. Acupuncturists were not
519 involved in patient recruitment in this trial. Patients and outcome assessors were blinded
520 to randomization. Patients were informed that they would receive one of two types of
521 acupuncture treatment: one was based on traditional Chinese acupuncture theories and
522 another was using modern acupuncture theory.

523 Acupuncture treatment was performed unilaterally, alternately at specific acupoints
524 of Waiguan (TE5), Yanglingquan (GB34), Qiuxu (GB40), and Fengchi (GB20), which

525 belong to Shaoyang Meridian of the hand and foot in the EA group (Figure 2A). Deqi
526 sensation was required for the EA group. In contrast, sham acupuncture treatment was
527 conducted unilaterally, alternately at predefined non-acupoints, including the middle
528 point between the tip of the elbow and the axilla, the middle point between the
529 epicondylus medialis of the humerus and the ulnar side of the wrist on the ulnar side, the
530 edge of the tibia 1 to 2 cm lateral to the Zusanli (ST36), and the anterior border of the
531 insertion of the deltoid muscle at the junction of the deltoid and biceps muscles in the
532 medial arm (Li *et al.*,2008) (Figure 2A). Deqi sensation was not required for the Sham
533 EA group. All acupoints and sham acupoints were punctured by disposable stainless steel
534 needles (0.25 mm × 40 mm; 0.25 mm × 25 mm; Suzhou Hwato Medical
535 Appliance Co., Ltd., 2270202, Suzhou City, China) at a depth of 20 mm-40 mm. In
536 addition to normal puncturing, 4 auxiliary needles were punctured 2 mm beside every
537 acupoint or non-acupoint with a depth of 2 mm without manual stimulation (Li *et*
538 *al.*,2008). Transcutaneous electroacupuncture stimulation was subsequently conducted at
539 the acupoints or sham acupoints for 30 minutes using a Han's acupoint nerve stimulator
540 (HANS-200, Nanjing, China) after needle insertion. The stimulation frequency was set at
541 2/15 Hz, and the intensity varied from 0.1 mA to 1 mA, adjusted in accordance with the
542 patient's perception. All acupuncture procedures were conducted in accordance with
543 standards for reporting interventions in clinical trials of acupuncture (STRICA)
544 (MacPherson *et al.*, 2010) and a predefined acupuncture SOP by a licensed acupuncturist
545 with at least 5 years of clinical acupuncture experience and with a completed
546 postgraduate degree. Acupuncture treatment was performed 5 times per week according
547 to the patient's convenience, and a total of 20 acupuncture treatments were performed on
548 both the EA and Sham EA groups. The patients were instructed not to take regular
549 medications during acupuncture treatment. However, ibuprofen (300 mg each capsule

550 with sustained release) could be used as rescue medication when severe migraine attacks
551 happened.

552

553 **Outcomes and sample collection**

554 The number of days with migraine before and after four weeks of treatment was
555 defined as the primary outcome for evaluating the frequency of migraine attack. This
556 outcome was recorded in a migraine diary by the migraine patients during the baseline
557 and four-week treatment period. Together with the number of days with migraine, the
558 frequency of migraine and the visual analog scale (VAS) were also recorded by the
559 migraine patients in the same period. The visual analog scale (VAS) is a validated and
560 reliable instrument for assessing pain severity and alleviation. On this scale, pain is
561 measured by placing a handwritten mark on a 10-centimeter line representing a
562 continuum between "no pain" (0 cm) and "worst pain" (10 cm) (10cm). This provides a
563 pain severity rating in centimeters out of ten, such as six out of ten (or 6/10) (Delgado *et*
564 *al.*, 2018). Measurements of the frequency and pain intensity of migraine were secondary
565 outcomes. A total of two blood samples were collected for metabolomics analysis at the
566 start of acupuncture treatment and at the end of 4 weeks of treatment. All fasting venous
567 blood samples (approximately 5 mL) were collected at approximately 7:30–9:30 am and
568 then stored at -80°C.

569

570 **NMR experiments**

571 ¹H NMR spectra of the plasma samples were collected and analysed as described in
572 our previous study (Gao *et al.*, 2014). 1 sample from acupuncture group (migraine
573 patients after acupuncture treatment) and 1 sample from sham acupuncture group
574 (migraine patients after sham acupuncture treatment) were not qualified to be analyzed

575 before experiment. Prior to NMR analysis, plasma samples were thawed and centrifuged
576 at $13000 \times g$, 4°C for 10min. $300 \mu\text{L}$ of each supernatant was transferred into 5mm NMR
577 tube, mixed with $250 \mu\text{L}$ of D_2O for field frequency lock and $50 \mu\text{L}$ of 3-trimethylsilyl-
578 $^2\text{H}_4$ -propionic acid sodium salt (TSP) in D_2O (1mg/mL) as chemical shift reference. All
579 samples contained a final volume of $600 \mu\text{L}$ and were vortexed repeatedly.

580 ^1H NMR data of plasma were acquired on a Varian INOVA 600 MHz NMR
581 spectrometer at 27°C using a Carr-Purcell-Meiboom-Gill (CPMG) spin-echo pulse
582 sequence, with a total spin-spin relaxation delay ($2n\tau$) of 320 ms. Water suppression was
583 achieved by selective saturation of the water peak during the recycle delay (2s) and
584 mixing time $^{\text{TM}}$ of 150 ms. Free induction decays (FIDs) were collected into 32,000 data
585 points with a spectral width of 8,000Hz over 64 scans. The FIDs were then zero-filled by
586 a factor of two and multiplied by an exponential line-broadening factor of 0.5Hz prior to
587 Fourier transformation. The diffusion-edited experiments were also carried out with
588 bipolar pulse pair-longitudinal eddy current delay (BPP-LED) pulse sequence. The
589 gradient amplitude was set at 35.0 G/cm with a diffusion delay of 100 ms. A total of 128
590 transients and 16,000 data points were collected with a spectral width of 8,000 Hz. A
591 line-broadening factor of 1 Hz was applied to FIDs before Fourier transformation (Wang
592 *et al.*, 2004).

593 All NMR spectra were manually phased and baseline-corrected using VNMR 6.1C
594 software (Varian Inc.). For CPMG spectra, each spectrum over the range of δ 0.4–4.4
595 was integrated into segments of equal width (0.01 ppm). The spectrum between δ 5.2–8.5
596 was discarded due to the weak signal of aromatic amino acids and the potential lack of
597 association with migraine according to previous studies (Dejong *et al.*, 2007; Harder *et*
598 *al.*, 2021). For BPP-LED data, each spectrum over the range of δ 0.1–6.0 was segmented
599 into integral regions of equal width (0.01ppm). The regions containing the residual

600 signals of water (δ 4.6–5.1) were excluded. Interval correlation shifting (icoshift)
601 technique in MATLAB package (version 7.0) were employed to conduct peak alignment.
602 It uses a Fast Fourier Transform (FFT) engine and a greedy algorithm that allows align
603 all spectra simultaneously (Savorani *et al.*,2010). To accommodate these large intensity
604 or concentration variations, the integral values of each spectrum were normalized to a
605 constant sum of all integrals in a spectrum in order to minimize the impacts of
606 concentration variation between samples after ppm segmentation. This total spectrum
607 area (TSA) normalization method performed well in representing NMR spectral
608 intensities (Emwas *et al.*,2018). Identification of metabolites in the spectra was achieved
609 based on literatures and the Chenomx NMR Suite 4.5 (Chenomx, Calgary, Canada) and
610 the HMDB database (<http://www.hmdb.ca/>). Specific compounds with multiple peaks
611 were determined by combining the relevant ppm corresponding to the most obvious
612 peaks in the normalized data. Figure 2B identifies and displays the major plasma
613 metabolites. The CPMG pulse sequence was used to emphasize the resonances of small
614 metabolites in plasma, while resonances from macromolecules were attenuated (Figure
615 2B). Supplementary Figure 1 shows diffusion-edited NMR spectra of plasma from each
616 group, displaying the signals of lipid, N-acetylglycoproteins (NAc) groups of
617 glycoproteins. Subtle differences in these spectra were observed by visual examination
618 among groups. Following the identification of metabolites, relative concentration of
619 metabolites could be estimated by the defined area of peak among different group.
620 Further analysis was conducted using supervised learning statistical techniques to
621 discriminate potential metabolic differences among the four groups.

622

623 **Statistical analysis**

624 **Clinical statistics**

625 The overall statistical strategy used in this study is shown in Figure 1. The clinical
626 variables were analyzed using R software (version 3.54). The baseline characteristics and
627 clinical outcomes were based on the intention-to-treat (ITT) population. We omitted the
628 cases that retained only the baseline measurement but had missing data in all clinical
629 outcomes. If the data were normally distributed, we planned to use ANOVA to detect the
630 differences in numerical variables and performed χ^2 tests for categorical variables. If data
631 were not normally distributed, we planned to apply the Kruskal-Wallis test. Continuous
632 data were described as the mean (SD) with 95% CIs. Categorical data were illustrated as
633 numbers and percentages. A one-sided test was executed for available data under
634 hypothesis testing in superiority. A P-value <0.05 was defined as statistically significant.
635 Clinical effect sizes were calculated by the R package “effectsize” using the cohen.d
636 method (Ben *et al.*,2020). The standardized effect size is defined as the difference in
637 means between two groups divided by the pooled standard deviation. The minimal
638 important difference (MID) for the VAS was calculated and defined by the empirical
639 work from Thorlund et al (2011), and it stands for the smallest difference in pain relief
640 that patients regarded as important on average.

641

642 **Pattern recognition**

643 The resulting integral data were transformed into SIMCA-P (version 14.0; Umetrics,
644 Ume^oa, Sweden) for pattern recognition analysis. Before analysis, CPMG data and BPP-
645 LED data were Pareto-scaled, in terms of variance stabilization (Worley B, *et al.*,2013).
646 For the purpose of discriminating differences in metabolic profiling among the groups,
647 CPMG data and LED data were both subjected to principal component analysis (PCA).
648 To detect and exclude the outlier of abnormal metabolic profile among included migraine
649 patients, PCA was first performed on the normalized ¹H NMR dataset after Pareto scaling

650 in this study (Mickiewicz B, *et al.*,2013). A principal component (PC) score plot and
651 loading plot were used to visualize the data. On the score plot, each point represents an
652 individual sample, and on the loadings plot, each point indicates a single NMR spectral
653 region. In the score plot, R^2Y displayed the proportion of the sum of squares for the
654 selected component, which accounts for the proportion of the variance in the responsible
655 (y) variable explained by the regression model (Figure S2A,B) (Wang *et al.*,2004).
656 Furthermore, OPLS-DA was performed to maximize separation and remove variance that
657 was not related to group membership. CV-ANOVA method was also carried out for the
658 cross-validation of OPLS-DA analysis within SIMCA-P software. Metabolites with an
659 impact on differentiation were ranked on the basis of the variables of importance
660 parameter (VIP) method coupled with OPLS-DA, which assesses each variable's relative
661 influence on the model. The metabolites with a value of $VIP > 1$ were selected and listed
662 as potential biomarkers for the discrimination of model (Menni *et al.*,2017).

663

664 **Biomarker discovery and validation**

665 To discover potential metabolite biomarkers for the effects of acupuncture, we
666 developed a strict statistical machine learning strategy that is used for this study (see
667 supplementary Fig. S4). Initially, the Shapiro-Wilks test was performed on raw data to
668 check the normal distribution. Following that, OPLS-DA analysis and VIP method are
669 conducted to achieve discrimination between groups and select potential biomarkers.
670 After obtaining the list of potential metabolic biomarkers for migraine and acupuncture
671 from VIP method, a Lasso regression was performed on the normalized metabolomic
672 data using the glmnet package in R to identify the most significant metabolites
673 determinants of change for migraine and acupuncture. The overall penalty parameter α
674 was set to 1 to select those with the highest predicted value of metabolites in glmnet.

675 Tenfold internal cross-validation with `cv.glmnet` function was applied to validate the
676 regression model and to achieve the minimum λ , the best predict parameter for
677 Lasso regression in the model. Through using this minimum λ yielded the most optimized
678 model, the most relevant metabolites distinguishing migraine, acupuncture and sham
679 acupuncture could be subsequently selected (Friedman *et al.*,2010). For the validation of
680 potential metabolic biomarkers, ANOVA with Box-Cox transformed method was
681 subsequently performed on these metabolites to obtain the Bonferroni-corrected P-value
682 with the `Mass` package in R (Venables *et al.*,2002; Blaise *et al.*,2016). Following the
683 analysis from VIP method, LASSO regression and ANOVA, a Venn diagram was
684 generated to determine the overlapping metabolites selected by three aforementioned
685 statistical methods (Supplementary Fig. S4). The overlap of statistically significant
686 metabolites ($P < 0.05$ after Bonferroni correction) common to all three statistical
687 methods were identified as validated biomarkers of migraine and acupuncture. Finally,
688 receiver operating characteristic (ROC) curve analysis was performed to evaluate the
689 diagnostic abilities of these validated biomarkers for migraine and acupuncture.
690 GraphPad Prism version 7.0 (GraphPad Software, United States) was used to perform this
691 ROC analysis. For the calculated area under the curve (AUC) of the biomarker, an AUC
692 of 0.9–1.0 suggested excellent performance, and 0.8–0.89 indicated good performance,
693 while $AUC < 0.6$ showed nonsignificant diagnostic performance (Haase-Fielitz *et*
694 *al.*,2009). Employing this consistent statistical strategy, we were able to subsequently
695 select and narrow the potential biomarkers from series of metabolites and pinpointed the
696 most validated biomarkers for migraine and acupuncture (Yu Y *et al.*, 2020).

697

698 **Pathway and network analysis**

699 Ingenuity Pathway Analysis (IPA) software (IPA build version: 364062M, content
700 version: 26127183, release date: 2015-12-12, analysis date: 2018-11-30,
701 <http://www.ingenuity.com/>) (QIAGEN, Redwood City, CA, USA) was used to explore
702 potential targeted pathways and networks related to both migraine and the effect of
703 acupuncture in an unbiased way. The ratios of metabolites between two groups, including
704 healthy controls vs. migraine group, acupuncture group vs. migraine group, acupuncture
705 group vs. sham acupuncture group, were calculated and inputted into IPA software for
706 pathway analysis of migraine and the efficacy of acupuncture. IPA's Core Analysis
707 module was subsequently used for pathway analysis. Fisher's exact test was used to
708 produce a P-value determining the probability that the link between the metabolites and
709 the canonical pathway was explained only by chance. Canonical pathways with a *P*-value
710 < 0.05 after Bonferroni correction were regarded as statistically significant pathways
711 contributing to the pathology of migraine and the potential effect of acupuncture. Based
712 on the 'master' network, which was developed from the Ingenuity Knowledge Base, a
713 causal network was established to reflect observed cause-effect relationships among
714 chemicals, protein families, complexes and biological processes. The network score was
715 calculated using the hypergeometric distribution, with Fisher's exact test at the right tail
716 yielding the negative logarithm of the significant threshold. Z-score > 2 was defined as
717 the threshold of significant activation for network analysis, disease, and function, while
718 Z-score < 2 was defined as the threshold of significant inhibition. The score of the
719 networks also reflects the probability of molecules gathering in this network. When the
720 number of metabolites gathering in this network increases, the score will also increase
721 (Krämer *et al.*,2014; Kriebel *et al.*,2016). Following the IPA analysis, the summary of
722 significant pathways and important networks were presented in the supplementary Fig.
723 S3.

724

725 **Data and availability**

726 All data, models, or code used during the study are available from the corresponding
727 author by request.

728

729 **Acknowledgements**

730 We grateful acknowledge Prof. Xuguang Liu, Prof. Qiaofeng Wu, Prof. Zongxiang
731 Tang, Prof. Xiaopei Shen, Prof. Fangrong Yan for their help and guide during the
732 experiment. We thank the staff from Top Grade TCM Science Technology Laboratory
733 of State Administration of TCM of China for the collection of blood samples of the
734 subjects.

735

736 **Funding**

737 This work was supported by grants from the National Basic Research Program of China
738 (973 Program, nos. 2012CB518501 and 2006CB504501), National Natural Science
739 Foundation of China (no. 81973941, no. 81202741), State Scholarship Fund (no.
740 201608320044).

741

742 **Author Contributions**

743 Jointly supervised research, F.L, S.Y, X.Y, C.G.; Conceived and designed the
744 experiments, F.L, S.Y, X.Y.; Performed the experiments, Z.G, Q.C, L.J, X.Y; Performed
745 statistical analysis, Z.G, C.M, C.G.; Contributed reagents, materials, or analysis tools,
746 R.W.S, S.S, S.M, B.K, R.W, J.A, S.B.; Contributed to data exploration, Z.G, G.Y, F.G,
747 L.J,U.M,C.G.; Wrote the paper, Z.G., X.Y, C.G. All authors discussed the results and
748 reviewed the final manuscript.

749

750 **Figure Titles and Legends**

751 **Fig. 1 Study design**

752 We conducted a non-targeted metabolomic study of 40 migraine patients and 10 healthy
753 people. Plasma was collected before and after EA or Sham EA treatment for ^1H NMR
754 experiments.

755

756 **Fig. 2: Locations of acupuncture points and typical ^1H NMR spectra of plasma 757 samples.**

758 (A) Locations of acupuncture points at Shaoyang meridian and non-acupoints

759 (B) Typical ^1H NMR CPMG spectra of plasma samples.

760 ^1H NMR experiments were carried out, and Chenomx NMR Suite 4.5 (Chenomx,
761 Calgary, Canada) software was used to identify 22 metabolites measured in a total of 50
762 plasma samples from 40 migraine patients and 10 healthy controls before and after EA or
763 sham EA treatment (Table 2). a1, migraine patients; ZC, healthy controls; Ala, alanine;
764 Cr/Crn, creatine; Gly, glycine; gln, glutamine; glu, glutamate; Val, valine; 3-HB, 3-
765 hydroxybutyric acid; Leu/Ile, isoleucine; Different citrate levels of migraine patients
766 indicate that there is a difference at the citrate level in the spectra.

767

768 **Fig. 3 Clear separation of metabolic profiles among groups.**

769 OPLS-DA analysis for CPMG data manifested clear separation among migraine patients
770 (red dots), healthy controls (black boxes), migraine patients after 4 weeks of EA
771 treatment (blue diamonds), and migraine patients after 4 weeks of sham EA treatment
772 (purple stars). t[1] and t[2] represent the first and second components in the OPLS-DA
773 result, respectively.

774 The missing samples from the EA group and Sham EA group on the score plots were
775 excluded due to the outlier and drop out.

776 (A) Clear separation of metabolic profiling was achieved between migraine (red dots,
777 n=40) and healthy control (black boxes, n=10) groups.

778 (B) Corresponding loading plots showing metabolites that may influence the separation
779 for (a). Gly, glycine; Gln, glutamine; Lac, lactic acid; Ala, alanine.

780 (C) The separation of metabolic profiling showed that EA treatment (blue diamonds,
781 n=22) reversed the change in metabolic profiling in migraine patients (red dots, n=22)
782 compared with healthy controls (black boxes, n=10) (Table 3).

783 (D) The results showed a clear discrimination in metabolic profiling between migraine
784 patient after EA treatment (blue diamonds, n=22) and migraine patients before EA
785 treatment (red dots, n=22) (Table 3).

786 (E) The results showed that migraine patient after sham EA treatment (purple stars, n=18)
787 could not restore the change of metabolic profiling in migraine patient before sham EA
788 treatment (red dots, n=18) compared with healthy controls (black boxes, n=10) (Table 4).

789 (F) The result showed metabolic profiling of migraine patient before Sham EA treatment
790 (red dots, n=18) could not be discriminated with migraine patient after Sham EA
791 treatment (purple stars, n=10) (Table 4)

792 (G) The profiling indicated that the metabolic profiling of migraine patients after EA
793 treatment (blue diamonds) was closer to that of healthy controls (black boxes) compared
794 to migraine patients after sham EA treatment (purple stars).

795 (H) Clear separation of metabolic profiling was discriminated between EA treatment
796 (blue diamonds) and sham EA treatment (purple stars) (Table 5).

797

798 **Fig. 4 Identification of significant metabolites for the clinical efficacy of acupuncture**

799 We conducted receiver operating characteristic (ROC) curve analysis to validate the
800 significance of potential biomarkers for migraine and acupuncture.

801 (A) ROC analysis showed that citrate could significantly discriminate the migraine and
802 control groups and thus might be a potential diagnostic biomarker (AUC=0.87) for
803 migraine diagnosis.

804 (B) Citrate was significantly decreased ($P = 0.00079$) after EA treatment.

805 (C) Employing IPA network analysis, we found that glycerine (glycerol), glycine,
806 acetone, alanine and leucine might be important metabolites for the metabolic network of
807 EA vs sham EA. Glycerine (glycerol), which is located near the centre of the metabolic
808 network of EA vs sham EA, may be the key metabolite for the efficacy of EA and sham
809 EA (C) (Table 5).

810

811 **Fig. 5 The metabolic mechanism for the efficacy of acupuncture in migraine**

812 The black arrow (\uparrow/\downarrow) shows the depletion of glucose metabolism and increased lipid
813 metabolism in migraine patients, leading to energy deficiency and disorder of the TCA

814 cycle and mitochondria, which trigger migraine attack. The red arrow (\uparrow/\downarrow) and the blue
815 box indicate the possible metabolic mechanism of acupuncture, which suggests that EA
816 may restore energy deficiency by enhancing anaerobic glycolysis and lowering plasma
817 citrate levels in the TCA cycle, thus decreasing migraine attack and restoring
818 mitochondrial function and metabolic profiling in migraine patients.

819

820 **Tables**

821 **Table 1. Clinical outcome measurements between the EA and Sham EA groups**
822 **before and after treatment**

823

824 **Table 2. Changes in plasma metabolites in CPMG NMR spectra between healthy**
825 **controls and migraine patients**

826

827 **Table 3. Changes in plasma metabolites in CPMG NMR spectra before and after**
828 **EA treatment in migraine patients**

829

830 **Table 4. Changes in plasma metabolites in CPMG NMR spectra before and after**
831 **sham acupuncture treatment in migraine patients**

832

833 **Table 5. Changes in plasma metabolites in CPMG NMR spectra between EA and**
834 **sham EA treatment**

835

836 **Supplementary information**

837 Supplementary Fig. S1 Typical ^1H NMR LED spectra of plasma samples.

838 Supplementary Fig. S2 Clear separation of metabolic profiles among groups.

839 Supplementary Fig. S3 Identification of significant pathway among three groups.

840 Supplementary Fig. S4 Statistical strategy for integrating different set of metabolic
841 biomarkers from diverse statistical methods in the study.

842 Supplementary Table S1. Baseline characteristics.

843 Supplementary Table S2. Changes in plasma metabolites in LED NMR spectra between
844 healthy controls and migraine patients

845 Supplementary Table S3. Changes in plasma metabolites in LED NMR spectra before
846 and after EA treatment in migraine patients.

847 Supplementary Table S4. Changes in plasma metabolites in LED NMR spectra before
848 and after sham acupuncture treatment in migraine patients

849 Supplementary Table S5. Changes in plasma metabolites in LED NMR spectra between
850 EA and sham EA treatment

851 Supplementary Table S6. cv-anova results of OPLS-DA analysis corresponding for score
852 plots

853

854 **Reference**

855 Alam Z, Coombes N, Waring RH, Williams AC, Steventon GB. Plasma levels of
856 neuroexcitatory amino acids in patients with migraine or tension headache. *J Neurol*
857 *Sci* 1998; 156:102-106.

858 Aroke EN, Powell-Roach KL. The Metabolomics of Chronic Pain Conditions: A
859 Systematic Review. *Biol Res Nurs* 2020; 15:1-14.

860 Aurora SK, Wilkinson F. The brain is hyperexcitable in migraine. *Cephalalgia* 2007;
861 27:1442–53.

862 Bélanger M, Allaman I, Magistretti PJ. Brain energy metabolism: focus on astrocyte-
863 neuron metabolic cooperation. *Cell Metab* 2011; 14:724–738.

864 Ben-SM, Makowski D, Lüdecke D. “Compute and interpret indices of effect size.”
865 CRAN 2020;R package, <https://github.com/easystats/effectsize>

866 Blaise BJ, Correia G, Tin A, Young JH, Vergnaud AC, Lewis M, Pearce JT, Elliott P,
867 Nicholson JK, Holmes E, Ebbels TM. Power Analysis and Sample Size Determin
868 ation in Metabolic Phenotyping. *Anal Chem* 2016; 17:5179-88.

869 Chen SP, Zhou YQ, Liu DQ, Zhang W, Manyande A, Guan XH, Tian YK, Ye DW,
870 Omar DM. PI3K/Akt Pathway: A Potential Therapeutic Target for Chronic Pain.
871 *Curr Pharm Des* 2017; 23:1860-1868.

872 Colombo B, Saraceno L, Comi G. Riboflavin and migraine:the bridge over troubled
873 mitochondria, *Neurol Sci* 2014; 35: Suppl 1,141-144.

874 Delgado DA, Lambert BS, Boutris N, McCulloch PC, Robbins AB, Moreno MR, Harris
875 JD. Validation of Digital Visual Analog Scale Pain Scoring With a Traditional Paper-
876 based Visual Analog Scale in Adults. *J Am Acad Orthop Surg Glob Res Rev*.
877 2018;2(3):e088.

878 Dejong CH, van de Poll MC, Soeters PB, Jalan R, Olde Damink SW. Aromatic amino
879 acid metabolism during liver failure. *J Nutr*. 2007;137(6 Suppl 1):1579S-1585S

- 880 Emwas AH, Saccenti E, Gao X, McKay RT, Dos Santos VAPM, Roy R, Wishart DS.
881 Recommended strategies for spectral processing and post-processing of 1D 1H-NMR
882 data of biofluids with a particular focus on urine. *Metabolomics*. 2018;14(3):31.
- 883 Fei YT, Cao HJ, Xia RY, Chai QY, Liang CH, Feng YT, Du YR, Yu MK, Guyatt G,
884 Thabane L, Lao LX, Liu JP, Zhang YQ. Methodological challenges in design and
885 conduct of randomised controlled trials in acupuncture. *BMJ*. 2022;376:e064345.
- 886 Finsterer J, Zarrouk-Mahjoub S. Headache in mitochondrial disorders. *Clin Neurol*
887 *Neurosurg*. 2018;166:44-49.
- 888 Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models
889 via C-ordinate Descent. *J Stat Softw* 2010; 33:1-22.
- 890 Gao Z, Liu X, Yu S, Zhang Q, Chen Q, Wu Q, Liu J, Sun B, Fang L, Lin J, Zhu BM, Yan
891 X, Liang F. Electroacupuncture at Acupoints Reverses Plasma Glutamate, Lipid, and
892 LDL/VLDL in an Acute Migraine Rat Model: A (1) H NMR-Based Metabolomic
893 Study. *Evid Based Complement Alternat Med* 2014; 2014:1-14.
- 894 Goldman N, Chen M, Fujita T, Xu Q, Peng W, Liu W, Jensen TK, Pei Y, Wang F, Han X,
895 Chen JF, Schnermann J, Takano T, Bekar L, Tieu K, Nedergaard M. Adenosine A1
896 receptors mediate local anti-nociceptive effects of acupuncture. *Nat Neurosci*.
897 2010;13(7):883-8.
- 898 Gross EC, Lisicki M, Fischer D, Sándor PS, Schoenen J. The metabolic face of migraine
899 - from pathophysiology to treatment. *Nat Rev Neurol* 2019;15:627-643.
- 900 Haase-Fielitz A, Bellomo R, Devarajan P, Story D, Matalanis G, Dragun D, Haase
901 M. Novel and conventional serum biomarkers predicting acute kidney injury in adult
902 cardiac surgery-a prospective cohort study. *Crit. Care Med* 2009; 37:553-560.
- 903 Harder AVE, Vijfhuizen LS, Henneman P, Willems van Dijk K, van Duijn CM, Terwindt
904 GM, van den Maagdenberg AMJM. Metabolic profile changes in serum of migraine
905 patients detected using 1H-NMR spectroscopy. *J Headache Pain*. 2021 Nov
906 24;22(1):142.
- 907 Headache Classification Subcommittee of the International Headache Society. The
908 international classification of headache disorders: 2nd edition. *Cephalalgia* 2004;
909 24:9-160.

- 910 Hockaday JM, Williamson DH, Whitty CW. Blood-glucose levels and fatty-acid
911 metabolism in migraine related to fasting. *Lancet* 1971; 297:1153–1156.
- 912 Huang C, Wang Y, Han JS, Wan Y. Characteristics of electroacupuncture-induced
913 analgesia in mice: variation with strain, frequency, intensity and opioid involvement.
914 *Brain Res.* 2002;945:20-25.
- 915 Krämer A, Green J, Pollard J Jr, Tugendreich S. Causal analysis approaches in Ingenuity
916 Pathway Analysis. *Bioinformatics* 2014; 15: 523-30.
- 917 Kriebel J, Herder C, Rathmann W, Wahl S, Kunze S, Molnos S, Volkova N, Schramm K,
918 Carstensen-Kirberg M, Waldenberger M, Gieger C, Peters A, Illig T, Prokisch H,
919 Roden M, Grallert H. Association between DNA Methylation in Whole Blood and
920 Measures of Glucose Metabolism: KORA F4 Study. *PLoS One.* 2016 Mar
921 28;11(3):e0152314. doi: 10.1371/journal.pone.0152314.
- 922 LeWitt PA, Li J, Lu M, Guo L, Auinger P; Parkinson Study Group–DATATOP
923 Investigators. Metabolomic Biomarkers as Strong Correlates of Parkinson Disease
924 Progression. *Neurology* 2017; 88:862-869.
- 925 Linde K, Streng A, Jürgens S, Hoppe A, Brinkhaus B, Witt C, Wagenpfeil S, Pfaffenrath
926 V, Hammes MG, Weidenhammer W, Willich SN, Melchart D. Acupuncture for
927 patients with migraine: a randomized controlled trial. *JAMA* 2005; 293: 2118-2125.
- 928 Linde K, Allais G, Brinkhaus B, Fei Y, Mehring M, Vertosick EA, Vickers A, White AR.
929 Acupuncture for the prevention of episodic migraine. *Cochrane Database Syst Rev*
930 2016; 6:CD001218.
- 931 Linde K. Evidence of effectiveness but not efficacy - why many complementary therapies
932 are so hard to accept for biomedicine. *BMC Complementary and Alternative*
933 *Medicine* 2017; 17:S3.
- 934 Li Y, Liang F, Yu S, Liu X, Tang Y, Yang X, Tian X, Yan J, Sun G, Chang X, Zheng H,
935 Zhang H, Ma T. Randomized controlled trial to treat migraine with acupuncture:
936 design and protocol. *Trials* 2008;20:57.
- 937 Li Y, Zheng H, Witt CM, Roll S, Yu SG, Yan J, Sun GJ, Zhao L, Huang WJ, Chang XR,
938 Zhang HX, Wang DJ, Lan L, Zou R, Liang FR. Acupuncture for migraine prophylaxis:
939 a randomized controlled trial. *CMAJ* 2012; 184: 401-410.

- 940 Liu YY, Jiao ZY, Li W, Tian Q. PI3K/AKT signaling pathway activation in a rat model
941 of migraine. *Mol Med Rep* 2017; 16:4849-4854.
- 942 Lodi R, Tonon C, Testa C, Manners D, Barbiroli B. Energy metabolism in migraine.
943 *Neurol Sci* 2006; 27 Suppl 2: S82-85.
- 944 Luo HG, Chen JX, Zhang Q, Yue GX, Ding J, Zhang HT, Yan XZ, Zhao X, Meng ZZ.
945 Comparative study on effects of Xiaoyao Powder and its modified prescription on
946 plasma metabolomics of rats with chronic immobilization Stress. *Chinese Journal of*
947 *Integrative Medicine* 2013; 19:610-615.
- 948 MacPherson H, Altman DG, Hammerschlag R, Li Y, Wu T, White A, Moher D;
949 STRICTA Revision Group. Revised standards for reporting interventions in clinical
950 trials of acupuncture (stricta): extending the consort statement. *PLoS Med* 2010; 7: 1-
951 11.
- 952 Menni C, Migaud M, Kastenmüller G, Pallister T, Zierer J, Peters A, Mohny RP,
953 Spector TD, Bagnardi V, Gieger C, Moore SC, Valdes AM. Metabolomic Profiling of
954 Long-Term Weight Change: Role of oxidative Stress and Urate Levels in Weight
955 Gain. *Obesity* 2017; 25:618-1624.
- 956 Mickiewicz B, Vogel HJ, Wong HR, Winston BW. Metabolomics as a novel approach
957 for early diagnosis of pediatric septic shock and its mortality. *Am J Respir Crit Care*
958 *Med.* 2013;187(9):967-76.
- 959 Pearce J. Insulin induced hypoglycaemia in migraine. *J. Neurol. Neurosurg. Psychiatry*
960 1971; 34:154–156.
- 961 Peek AL, Rebbeck T, Puts NA, Watson J, Aguila MR, Leaver AM. Brain GABA and
962 glutamate levels across pain conditions: A systematic literature review and meta-
963 analysis of 1H-MRS studies using the MRS-Q quality assessment tool. *Neuroimage*
964 2020; 210:116532.
- 965 Salek T, Andel I, Kurfurstova I. Topiramate induced metabolic acidosis and kidney
966 stones - a case study. *Biochem Med (Zagreb)* 2017; 27:404-410.
- 967 Savorani F, Tomasi G, Engelsen SB. icoshift: A versatile tool for the rapid alignment of
968 1D NMR spectra. *J Magn Reson.* 2010;202(2):190-202.
- 969 Sedgwick P. Multiple hypothesis testing and Bonferroni's correction. *BMJ.* 2014;20:
970 349:g6284.

- 971 Sparaco M, Feleppa M, Lipton RB, Rapoport AM, Bigal ME. Mitochondrial dysfunction
972 and migraine: evidence and hypotheses. *Cephalalgia* 2006; 26:361-372.
- 973 Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, Alberini CM.
974 Astrocyte-neuron lactate transport is required for long-term memory formation. *Cell*.
975 2011;144(5):810-23.
- 976 Thorlund K, Walter SD, Johnston BC, Furukawa TA, Guyatt GH. Pooling Health-Related
977 Quality of Life Outcomes in Meta-Analysis-A Tutorial and Review of Methods for
978 Enhancing Interpretability. *Res Synth Methods* 2011; 3:188-203.
- 979 Venables, W. N. & Ripley, B. D. *Modern Applied Statistics with S*. Fourth Edition.
980 Springer 2002; New York. ISBN 0-387-95457-0.
- 981 Vickers AJ, Cronin AM, Maschino AC, Lewith G, MacPherson H, Foster NE, Sherman
982 KJ, Witt CM, Linde K; Acupuncture Trialists' Collaboration. Acupuncture for chronic
983 pain: individual patient data meta-analysis. *Arch Intern Med* 2012;172:1444-1453.
- 984 Vickers AJ, Linde K. Acupuncture for chronic pain. *JAMA* 2014; 311: 955-956.
- 985 Wang Y, Holmes E, Nicholson JK, Cloarec O, Chollet J, Tanner M, Singer BH, Utzinger
986 J. Metabonomic investigations in mice infected with *Schistosoma mansoni*: an
987 approach for biomarker identification. *Proc Natl Acad Sci U S A*. 2004; 101(34):
988 12676-81.
- 989 Wells RE, Bertisch SM, Buettner C, Phillips RS, McCarthy EP. Complementary and
990 alternative medicine use among adults with migraines/severe headaches. *Headache*
991 2011;51:1087-1097.
- 992 Worley B, Powers R. Multivariate Analysis in Metabolomics. *Curr Metabolomics*.
993 2013;1(1):92-107
- 994 Wu Q, Zou M, Yang M, Zhou S, Yan X, Sun B, Wang Y, Chang S, Tang Y, Liang F, Yu
995 S. Revealing Potential Biomarkers of Functional Dyspepsia by Combining 1H NMR
996 Metabonomics Techniques and an Integrative Multi-objective Optimization Method.
997 *Sci Rep* 2016; 6:18852.
- 998 Xu B, Mo C, Lv C, Liu S, Li J, Chen J, Wei Y, An H, Ma L, Guan X. Post-surgical
999 inhibition of phosphatidylinositol 3-kinase attenuates the plantar incision-induced
1000 postoperative pain behavior via spinal Akt activation in male mice. *BMC Neurosci*.
1001 2019; 20(36):1-10

- 1002 Xu W, Zhang L, Huang Y, Yang Q, Xiao H, Zhang D. Discrimination of type 2 diabetes
1003 mellitus corresponding to different traditional Chinese medicine syndromes based on
1004 plasma fatty acid profiles and chemometric methods. *Journal of Ethnopharmacology*
1005 2012; 143:463-468.
- 1006 Xu X, Chen Q, Qiu Z, Shi C, Ding H, Wang L, Lv H, Yu L. Association of cough
1007 hypersensitivity with tracheal TRPV1 activation and neurogenic inflammation in a
1008 novel guinea pig model of citric acid-induced chronic cough. *J Int Med Res* 2018;
1009 46:2913-2924.
- 1010 Yang J, Zeng F, Feng Y, Fang L, Qin W, Liu X, Song W, Xie H, Chen J, Liang F. A
1011 PET-CT study on the specificity of acupoints through acupuncture treatment in
1012 migraine patients. *BMC Complement Altern Med* 2012; 15:1-7.
- 1013 Yang M, Yu Z, Chen X, Guo Z, Deng S, Chen L, Wu Q, Liang F. Active Acupoints
1014 Differ from Inactive Acupoints in Modulating Key Plasmatic Metabolites of
1015 Hypertension: A Targeted Metabolomics Study. *Sci Rep* 2018; 8:17824.
- 1016 Yu H, Sang P, Huan T. Adaptive Box-Cox Transformation: A Highly Flexible Feature-
1017 Specific Data Transformation to Improve Metabolomic Data Normality for Better
1018 Statistical Analysis. *Anal Chem.* 2022;94(23):8267-8276.
- 1019 Yu Y, Gao Z, Lou J, Mao Z, Li K, Chu C, Hu L, Li Z, Deng C, Fan H, Chen P, Huang H,
1020 Yu Y, Ding J, Li D, Chen F. Identification of Serum-Based Metabolic Feature and
1021 Characteristic Metabolites in Paraquat Intoxicated Mouse Models. *Front Physiol.*
1022 2020;11:65.
- 1023 Zeng F, Qin W, Ma T, Sun J, Tang Y, Yuan K, Li Y, Liu J, Liu X, Song W, Lan L, Liu
1024 M, Yu S, Gao X, Tian J, Liang F. Influence of acupuncture treatment on cerebral
1025 activity in functional dyspepsia patients and its relationship with efficacy. *Am J*
1026 *Gastroenterol* 2012; 107:1236-1247.
- 1027 Zhao LP, Liu L, Pei P, Qu ZY, Zhu YP, Wang LP. Electroacupuncture at Fengchi (GB20)
1028 inhibits calcitonin gene-related peptide expression in the trigeminovascular system of
1029 a rat model of migraine. *Neural Regen Res* 2017; 12:804-811.
- 1030 Zhao L, Chen J, Li Y, Sun X, Chang X, Zheng H, Gong B, Huang Y, Yang M, Wu X, Li
1031 X, Liang F. The long-term effect of acupuncture for migraine prophylaxis: a
1032 randomized clinical trial. *JAMA Intern Med* 2017;177:508-515.

1033 Zhao, ZQ. Neural mechanism underlying acupuncture analgesia. *Prog. Neurobiol* 2008;
1034 85: 355–375.
1035

Figure. 1 Study design

We conducted a non-targeted metabolomic study of 40 migraine patients and 10 healthy people. Plasma was collected before and after EA or Sham EA treatment for ^1H NMR experiments.




Figure. 2: Locations of acupuncture points and typical ^1H NMR spectra of plasma samples.

(A) Locations of acupuncture points at Shaoyang meridian and non-acupoints

(B) Typical ^1H NMR CPMG spectra of plasma samples.

^1H NMR experiments were carried out, and Chenomx NMR Suite 4.5 (Chenomx, Calgary, Canada) software was used to identify 22 metabolites measured in a total of 50 plasma samples from 40 migraine patients and 10 healthy controls before and after EA or sham EA treatment (Table 2). a1, migraine patients; ZC, healthy controls; Ala, alanine; Cr/Crn, creatine; Gly, glycine; gln, glutamine; glu, glutamate; Val, valine; 3-HB, 3-hydroxybutyric acid; Leu/Ile, isoleucine; Different citrate levels of migraine patients indicate that there is a difference at the citrate level in the spectra.




Figure 3 Clear separation of metabolic profiles among groups.

OPLS-DA analysis for CPMG data manifested clear separation among migraine patients (red dots), healthy controls (black boxes), migraine patients after 4 weeks of EA treatment (blue diamonds), and migraine patients after 4 weeks of sham EA treatment (purple stars). $t[1]$ and $t[2]$ represent the first and second components in the OPLS-DA result, respectively. The missing samples from the EA group and Sham EA group on the score plots were excluded due to the outlier and drop out.

(A) Clear separation of metabolic profiling was achieved between migraine (red dots, $n=40$) and healthy control (black boxes, $n=10$) groups.

(B) Corresponding loading plots showing metabolites that may influence the separation for (a). Gly, glycine; Gln, glutamine; Lac, lactic acid; Ala, alanine.

(C) The separation of metabolic profiling showed that migraine patient after EA treatment (blue diamonds, $n=22$) reversed the change in metabolic profiling in migraine patients before EA treatment (red dots, $n=22$) compared with healthy controls (black boxes, $n=10$) (Table 3).


(D) The results showed a clear discrimination in metabolic profiling between migraine patient after EA treatment (blue diamonds, $n=22$) and migraine patients before EA treatment (red dots, $n=22$) (Table 3).

(E) The results showed that migraine patient after sham EA treatment (purple stars, $n=18$) could not restore the change of metabolic profiling in migraine patient before sham EA treatment (red dots, $n=18$) compared with healthy controls (black boxes, $n=10$) (Table 4).

(F) The result showed metabolic profiling of migraine patient before Sham EA treatment (red dots, $n=18$) could not be discriminated with migraine patient after Sham EA treatment (purple stars, $n=18$) (Table 4)

(G) The profiling indicated that the metabolic profiling of migraine patients after EA treatment (blue diamonds) was closer to that of healthy controls (black boxes) compared to migraine patients after sham EA treatment (purple stars).

(H) Clear separation of metabolic profiling was discriminated between EA treatment (blue diamonds) and sham EA treatment (purple stars) (Table 5).






Figure. 4 Identification of significant metabolites for the clinical efficacy of acupuncture

We conducted receiver operating characteristic (ROC) curve analysis to validate the significance of potential biomarkers for migraine and acupuncture.

(A) ROC analysis showed that citrate could significantly discriminate the migraine and control groups and thus might be a potential diagnostic biomarker (AUC=0.87) for migraine diagnosis.

(B) Citrate was significantly decreased ($P = 0.00079$) after EA treatment.

(C) Employing IPA network analysis, we found that glycerine (glycerol), glycine, acetone, alanine and leucine might be important metabolites for the metabolic network of EA vs sham EA. Glycerine (glycerol), which is located near the centre of the metabolic network of EA vs sham EA, may be the key metabolite for the efficacy of EA and sham EA (C) (Table 5).




Figure. 5 The metabolic mechanism for the efficacy of acupuncture in migraine

The black arrow (\uparrow/\downarrow) shows the depletion of glucose metabolism and increased lipid metabolism in migraine patients, leading to energy deficiency and disorder of the TCA cycle and mitochondria, which trigger migraine attack. The red arrow (\uparrow/\downarrow) and the blue box indicate the possible metabolic mechanism of acupuncture, which suggests that EA may restore energy deficiency by enhancing

anaerobic glycolysis and lowering plasma citrate levels in the TCA cycle, thus decreasing migraine attack and restoring mitochondrial function and metabolic profiling in migraine patients.




Table 1 Clinical outcome measurements between the EA and Sham EA groups before and after treatment

Outcome	EA group (n = 22[#])	Sham EA group (n = 18[#])	T value (EA vs Sham)	P value (EA vs Sham)	Effect size (EA vs Sham)
Number of days with migraine					
Baseline, mean,(sd),(95 % CI)	7.53(5.42) (4.25 to 10.81)	6.46(3.46) (4.54 to 8.38)	0.61	0.54	
End of treatment, mean, (sd),(95 % CI)	4.92(5.13) (1.81 to 8.02)	4.57(2.73) (2.99 to 6.15)	0.21	0.82	0.086(-0.71 to 0.88)
Difference in means End of treatment-baseline, mean, (sd), (95 % CI)	2.61(2.87) (0.87 to 4.35)	2.07(3.64) (-0.034 to 4.17)	0.43	0.66	0.16
t value	3.28	2.12			
P value	0.0065**	0.053			
Effect size	0.50 (0.17 to 0.82)	0.65(-0.042to 1.35)			
Frequency of migraines					
Baseline, mean, (sd), (95 % CI)	4.69(2.05) (3.44 to 5.93)	4.26(2.28) (3.00 to 5.53)	0.51	0.60	

End of treatment, mean, (sd), (95 % CI)	3.15(2.26) (1.78 to 4.52)	3.57(1.45) (2.73 to 4.41)	-0.56	0.57	0.22(-0.57 to 1.02)
End of treatment-baseline, mean, (sd), (95 % CI)	1.53(2.40) (0.086 to 2.98)	0.71(2.78) (-0.89 to 2.32)	0.82	0.41	0.32
t value	2.30	0.95			
P value	0.039*	0.35			
Effect size	0.71(7.03e-05 to 1.42)	0.36(-0.44 to 1.17)			
VAS score					
Baseline, mean, (sd), (95 % CI)	4.11(1.32) (3.31 to 4.91)	4.49(1.60) (3.63 to 5.35)	-0.70	0.48	
End of treatment, mean,(sd), (95 % CI)	3.24(1.53) (2.31 to 4.17)	4.29(1.95) (3.24 to 5.33)	-1.60	0.12	0.585(-0.19 to 1.36)
End of treatment-baseline, mean, (sd), (95 % CI)	0.86(1.99) (-0.33 to 2.07)	0.25(1.74) (-0.71 to 1.22)	0.85	0.40	0.33
t value	1.81	0.568			
P value	0.047*	0.573			
Effect size	0.61 (-0.26 to 1.47)	0.14 (-0.36 to 0.64)			

* $P < 0.05$; ** $P < 0.01$. # The baseline characteristics and clinical outcomes were based on the intention-to-treat (ITT) population. We omitted the cases that retained only the baseline measurement but had missing data for all clinical outcomes.

Table 2 Changes in plasma metabolites in CPMG NMR spectra between healthy controls and migraine patients

Metabolism	Metabolites	Peak Regions	Con (n=10) mean(sd)	Mig (n=40) mean(sd)	Direction of effect Mig vs Con	adjP Mig vs Con
	Glucose	3.89	173.93(12.32)	171.37(12.02)	↓	0.56
	Lactic acid	1.32	276.77(52.99)	266.91(55.56)	↓	0.62
Glucose	Nac	2.03-2.04	168.04(12.44)	161.05(13.89)	↓	0.16
metabolism	3-HB	1.19-1.20	35.50(31.16)	41.81(23.59)	↑	0.53
	Acetoacetate	2.22	16.24(14.15)	19.64(12.12)	↑	0.49
	Citrate	2.68-2.70	3.25(2.53)	5.73(2.79)	↑↑	0.016*
	Pyruvic acid	2.38	2.25 (1.63)	3.47(1.63)	↑↑	0.049*
	Acetate	1.91	9.16(3.82)	11.33(5.18)	↑	0.23
Lipid	Lipid	1.3	54.38(9.31)	42.78(15.32)	↓↓	0.030*
metabolism	Glycerine	3.64-3.66	70.28(11.46)	86.66(12.84)	↑↑	0.00085**
	Ptdcho	3.24	282.6(16.49)	289.60(12.72)	↑	0.16
	Choline	3.22-3.23	256.83(21.51)	284.53(26.08)	↑↑	0.00403**
	LDL_VLDL	0.86-0.88	158.52(21.80)	164.31(36.37)	↑	0.63
Amino acid	Glycine	3.54	239.82(14.61)	212.26(24.63)	↓↓	0.0017**
	Alanine	1.46	83.34(18.50)	61.05(18.75)	↓↓	0.0020**
	Glutamate	2.35-2.36	24.74(5.92)	25.05(7.41)	↑	0.90

metabolism	Valine	1.03-1.04	104.63(12.72)	103.51(16.66)	↓	0.85
	Leu_Ile	0.97-0.99	145.68(16.16)	143.82(21.32)	↓	0.81
	Glutamine	2.43-2.44	94.35(14.19)	88.95(15.23)	↓	0.32
	Cre/Crn	3.03-3.04	35.23(6.39)	38.81(7.72)	↑	0.19
	Isoleucine	0.94	33.51(3.71)	31.71(4.03)	↓	0.21
	Glutamine	2.11-2.12	68.37(11.86)	81.73(17.70)	↑↑	0.0017**

The up or down arrow (↑/↓) indicates whether the metabolite showed a signal increase or decrease, respectively. * $P < 0.05$; ** $P < 0.01$. Abbreviations: Con, healthy control; Mig, migraine patients from the EA and Sham EA groups before treatment; adjp, p value after Bonferroni correction.

Table 3 Changes in plasma metabolites in CPMG NMR spectra before and after EA treatment in migraine patients

Metabolism	Metabolites	Con (n=10) mean(sd)	Mig (n=22) mean(sd)	Direction of effect Con vs Mig	adjP Mig vs Con	EA	Direction of effect EA vs Con	adjP EA vs Con	Direction of effect EA vs Mig	adjP EA vs Mig
						mean(sd)				
	Glucose	173.93(12.32)	166.53(12.35)	↓	0.33	171.13(13.78)	↓	0.85	↑	0.58
	Lactic acid	276.76(53.0)	269.56(55.83)	↓	0.95	327.16(71.12)	↑	0.12	↑↑	0.031*
Glucose	Nac	168.04(12.43)	157.42(14.98)	↓	0.18	160.29(15.56)	↓	0.40	↑	0.85
metabolism	3-HB	35.50(31.16)	49.46(29.14)	↑	0.34	30.36(14.42)	↓	0.89	↓	0.097
	Acetoacetate	16.24(14.15)	21.11(15.45)	↑	0.58	9.26 (6.23)	↓	0.35	↓↓	0.025*

	Citrate	3.25(2.53)	7.24(2.37)	↑↑	0.00019**	4.02 (1.80)	↑	0.65	↓↓	0.00079**
	Pyruvic_acid	2.25 (1.63)	4.10 (1.93)	↑↑	0.022*	2.32 (1.36)	-	0.995	↓↓	0.012*
	Acetate	9.17(3.82)	11.34(5.60)	↑	0.45	10.17 (3.40)	↑	0.84		0.76
	Lipid	54.38 (9.31)	46.61(17.20)	↓	0.37	40.64(14.21)	↓	0.065	↓	0.49
Lipid metabolism	Glycerine	70.28(11.46)	89.79(12.67)	↑↑	0.00056**	92.26(11.55)	↑↑	0.00016**	↑	0.83
	Ptdcho	282.60(16.50)	288.13(11.53)	↑	0.63	283.87(17.76)	↓	0.98	↓	0.71
	Choline	256.83(21.51)	289.91(27.11)	↑↑	0.0053**	283.68 (24.5)	↑↑	0.031*	↓	0.76
	LDL_VLDL	158.52(21.80)	162.88(36.51)	↑	0.95	156.25(39.11)	↓	0.98	↓	0.85
	Glycine	239.82(14.61)	218.25(28.46)	↓	0.13	217.75(31.54)	↓	0.13	/	0.99
Amino acid metabolism	Alanine	83.34(18.5)	64.71(22.65)	↓	0.075	67.57(20.08)	↓	0.17	↑	0.91
	Glutamate	24.75(5.92)	25.32(8.54)	↑	0.98	26.42(8.87)	↑	0.87	↑	0.92
	Valine	104.63(12.72)	99.78(17.20)	↓	0.675	99.17(12.03)	↓	0.63	/	0.99
	Leu lle	145.68(16.16)	138.51(22.07)	↓	0.59	139.1(15.84)	↓	0.67	/	0.99
	Glutamine	94.35(14.18)	92.04(18.14)	↓	0.92	83.90(13.86)	↓	0.25	↓	0.33
	Cre_Crn	35.23(6.39)	42.09(8.33)	↑	0.083	36.30(7.95)	↑	0.94	↓	0.10
	Isoleucine	33.51(3.71)	31.14(4.86)	↓	0.33	32.14(3.41)	↓	0.70	↑	0.77
	Glutamine	68.37(11.86)	79.16(21.54)	↑↑	0.045*	73.89(13.72)	↑	0.24	↓	0.65

The up or down arrow (↑/↓) indicates whether the metabolite showed a signal increase or decrease, respectively. * $P < 0.05$; ** $P < 0.01$. Mig, migraine patients in

EA group before treatment; EA, migraine patients in the EA group after 4 weeks of EA treatment. Con, healthy control. adjp, p value after Bonferroni correction.

Table 4 Changes in plasma metabolites in CPMG NMR spectra before and after sham acupuncture treatment in migraine patients

Metabolism	Metabolites	Con mean(sd) (n = 10)	Mig mean(sd) (n = 18)	Directio n of effect Con vs Mig	adjP Mig vs Con	Sham EA mean(sd)	Direction of effect Sham EA vs Con	adjP Sham EA vs Con	Directi on of effect Sham EA vs Mig	adjP Sham EA vs Mig
Glucose metabolism	Glucose	173.94(12.32)	176.51(9.54)	↑	0.79	173.66(8.28)	-	0.99	↓	0.79
	Lactic acid	276.77(52.99)	264.10(56.97)	↓	0.85	285.55(89.8)	↑	0.99	↑	0.80
	Nac	168.04(12.43)	164.91(11.88)	↓	0.79	159.32(9.15)	↓	0.25	↓	0.49
	3-HB	35.50(31.16)	33.68(12.07)	↓	0.88	27.48(14.54)	↓	0.82	↓	0.50
	Acetoacetate	16.24(14.15)	18.08(7.32)	↑	0.54	16.72(12.50)	-	0.97	↓	0.71
	Citrate	3.25(2.53)	4.14(2.31)	↑	0.50	4.26(2.16)	↑	0.57	/	0.99
	Pyruvic acid	2.25(1.63)	2.81(0.86)	↑	0.29	1.83(1.22)	↓	0.64	↓↓	0.047**
	Acetate	9.16(3.82)	11.32(4.88)	↑	0.36	11.28(2.89)	↑	0.35	/	0.97
Lipid metabolism	Lipid	54.38(9.31)	38.71(12.27)	↓↓	0.011*	32.80(12.12)	↓↓	0.0012**	↓	0.39
	Glycerine	70.28(11.46)	83.33(12.54)	↑↑	0.019**	84.82(9.98)	↑↑	0.021*	↑	0.93
	Ptdcho	282.60(16.49)	291.15(14.08)	↑	0.30	286.37(12.2)	↑	0.82	↓	0.71
	Choline	256.83(21.51)	278.81(24.46)	↑	0.12	285.47(38.5)	↑	0.08	↑	0.88
	LDL_VLDL	158.52(21.81)	165.83(37.35)	↑	0.92	171.78(36.2)	↑	0.73	↑	0.89
	Glycine	239.82(14.61)	205.91(18.61)	↓↓	9.98498 E-05**	196.28(17.62)	↓	1.349E-05**	↓	0.34
	Alanine	83.34(18.5)	57.164(13.1)	↓↓	0.0014*	55.11(17.37)	↓↓	0.0016**	↓	0.87

Amino acid metabolism	Glutamate	24.75(5.92)	24.76(6.27)	-	0.99	24.044(4.51)	-	0.98	-	0.98	
	Valine	104.63(12.72)	107.46(15.62)	↑	0.91	108.07(15.7)	↑	0.89	-	0.99	
	Leu_Ile	145.69(16.16)	149.46(19.59)	↑	0.89	152.31(20.7)	↑	0.75	↑	0.93	
	Glutamine	94.35(14.19)	85.67(11.02)	↓	0.29	85.18(15.72)	↓	0.29	-	0.98	
	Cre_Crn	35.24(6.39)	35.33(5.315)	-	0.99	38.33(7.32)	↑	0.56	↑	0.54	
	Isoleucine	33.51(3.71)	32.33(2.95)	↓	0.69	31.64(3.86)	↓	0.44	↓	0.85	
	Glutamine	68.37(11.86)	84.47(12.57)	↑↑	5.302E-05**	88.57(14.04)	↑↑	1.36E-05**	↑	0.46	

The up or down arrow (↑/↓) indicates whether the metabolite showed a signal increase or decrease, respectively. * $P < 0.05$; ** $P < 0.01$. Mig, migraine patients in sham EA group before treatment; Sham EA, migraine patients in the sham EA group after 4 weeks of sham EA treatment. Con, healthy control. adjp, p value after Bonferroni correction.

Table 5 Changes in plasma metabolites in CPMG NMR spectra between EA and sham EA treatment

Metabolism	Metabolites	EA mean(sd)	Sham EA mean(sd)	Direction of effect EA vs Sham EA	adjP EA vs Sham EA	Coefficient EA vs Sham EA
Glucose metabolism	Glucose	171.13(13.78)	173.67(8.28)	↑	0.64	n.a.
	Lactic acid	327.17(71.12)	285.55(89.88)	↑	0.23	n.a.
	Nac	160.29(15.56)	159.32(9.15)	↓	0.85	n.a.
	3-HB	30.36(14.42)	27.48(14.54)	↓	0.64	-0.74
	Acetoacetate	9.26(6.23)	16.72(12.50)	↑	0.061	1.06
	Citrate	4.02(1.81)	4.26(2.16)	-	0.72	n.a.
	Pyruvic acid	2.32(1.36)	1.83(1.22)	↓	0.35	n.a.
Acetate	10.17(3.40)	11.29(2.90)	↑	0.43	n.a.	

	Lipid	40.64(14.22)	32.80(12.13)	↓	0.18	n.a.
Lipid	Glycerine	92.26(11.56)	84.824(9.98)	↓	0.12	-0.38
metabolism	Ptdcho	283.87(17.76)	286.38(12.21)	↑	0.72	n.a.
	Choline	283.68(24.50)	285.47(38.52)	↑	0.87	n.a.
	LDL_VLDL	156.25(39.12)	171.78(36.19)	↑	0.35	0.24
	Glycine	217.75(31.53)	196.29(17.62)	↓	0.076	-0.179
	Alanine	67.57(20.08)	55.12(17.37)	↓	0.14	-0.32
Amino acid	Glutamate	26.42(8.87)	24.04(4.51)	↓	0.43	n.a.
metabolism	Valine	99.17(12.03)	108.07(15.70)	↑	0.13	n.a.
	Leu_Ile	139.10(15.84)	152.31(20.75)	↑	0.088	0.19
	Glutamine	83.90(13.86)	85.18(15.72)	↑	0.83	n.a.
	Cre_Crn	36.30(7.95)	38.34(7.32)	↑	0.55	n.a.
	Isoleucine	32.14(3.41)	31.64(3.86)	↓	0.75	n.a.
	Glutamine	73.89(13.72)	88.56(14.04)	↑↑	0.0098**	0.23

The up or down arrow (↑/↓) indicates whether the metabolite showed a signal increase or decrease, respectively. * $P < 0.05$; ** $P < 0.01$.

The coefficient was calculated by Lasso regression. EA, migraine patients in the EA group after 4 weeks of EA treatment; Sham EA, migraine patients in the Sham EA group after 4 weeks of Sham EA treatment.